Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.56
+3.7%
$0.67
$0.50
$1.95
$5.97M1.632,776 shs1,601 shs
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$5.47
+4.4%
$5.80
$2.68
$8.22
$172.31M4.06386,182 shs259,837 shs
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.04
$0.04
$0.03
$0.09
$515K0.546,924 shs417 shs
MYOS
MYOS RENS Technology
$3.35
$0.74
$3.85
$16.70M1.081.68 million shsN/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
+4.62%0.00%-13.28%+1.01%-14.62%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
+4.39%+1.11%-19.56%+37.96%+42.45%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
-7.89%-18.60%-14.22%-12.50%-35.90%
MYOS
MYOS RENS Technology
0.00%0.00%0.00%-23.89%+686.45%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
1.0843 of 5 stars
3.50.00.00.02.40.80.6
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2.00
HoldN/AN/A
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
3.00
Buy$24.00338.76% Upside
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ADXS, MYOS, CAPR, and KAYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
3/1/2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$10K596.63N/AN/A($2.27) per share-0.24
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$25.18M6.84N/AN/A$0.73 per share7.49
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$200K2.58$0.12 per share0.30($1.07) per share-0.03
MYOS
MYOS RENS Technology
$1.03M0.00N/AN/A$0.13 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$22.29M-$0.87N/A45.58N/A-88.52%-299.67%-45.54%5/9/2024 (Estimated)
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$1.61M-$0.02N/AN/A821.43%-9.57%638.26%N/A
MYOS
MYOS RENS Technology
-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/A

Latest ADXS, MYOS, CAPR, and KAYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A-$2.96-$2.96-$2.96N/AN/A
4/16/2024Q4 2023
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A$0.01+$0.01$0.01N/A$0.03 million
2/29/2024Q4 2023
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A
0.30
0.30
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A
1.63
1.63
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
MYOS
MYOS RENS Technology
0.11
3.78
1.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
21.68%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
MYOS
MYOS RENS Technology
4.97%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
12.00%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
MYOS
MYOS RENS Technology
45.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A10.75 million10.68 millionNot Optionable
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A31.50 million27.72 millionOptionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
414.72 million11.26 millionNot Optionable
MYOS
MYOS RENS Technology
1512.19 millionN/ANot Optionable

ADXS, MYOS, CAPR, and KAYS Headlines

SourceHeadline
Ren Zhengfei says US government underestimates HuaweiRen Zhengfei says US government 'underestimates' Huawei
bbc.com - December 23 at 1:17 PM
Pioneer announces The Ren as Business Partner of the YearPioneer announces The Ren as Business Partner of the Year
richlandsource.com - November 20 at 1:50 PM
Shenqiang RenShenqiang Ren
buffalo.edu - October 4 at 3:32 PM
Anthony M. Newman to Lead REN-ISAC Cybersecurity CenterAnthony M. Newman to Lead REN-ISAC Cybersecurity Center
campustechnology.com - August 27 at 9:26 PM
Carbon-based quantum technologyCarbon-based quantum technology
sciencedaily.com - August 19 at 4:05 PM
Bio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]Bio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]
marketwatch.com - May 11 at 1:13 AM
Latest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraints
marketwatch.com - May 8 at 9:06 PM
Bio-active Peptides Market Size Dynamics 2023-2029Bio-active Peptides Market Size Dynamics 2023-2029
marketwatch.com - April 13 at 3:09 PM
RenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platform
cointelegraph.com - April 6 at 1:03 PM
Global Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027Global Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027
marketwatch.com - March 21 at 9:47 AM
Bio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027Bio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027
marketwatch.com - March 13 at 10:33 AM
Can Huawei thrive despite American sanctions?Can Huawei thrive despite American sanctions?
economist.com - October 29 at 10:12 AM
Bio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028Bio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028
marketwatch.com - September 28 at 9:57 AM
Bio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries DataBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Data
marketwatch.com - August 4 at 1:49 AM
Renaissance Festival tickets go on sale Friday, Aug. 5Renaissance Festival tickets go on sale Friday, Aug. 5
independenttribune.com - August 1 at 9:38 AM
Rensair raises $7m to establish clean air as a human rightRensair raises $7m to establish clean air as a human right
wfmz.com - May 10 at 9:43 AM
Bioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026Bioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026
wicz.com - January 12 at 2:06 PM
Bioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.Bioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.
chipdesignmag.com - November 1 at 10:13 PM
ICYMI: Everything you need to know about the iPhone 13ICYMI: Everything you need to know about the iPhone 13
yahoo.com - September 26 at 10:38 PM
MYOS RENS Technology Inc. Common Stock (MYOS)MYOS RENS Technology Inc. Common Stock (MYOS)
nasdaq.com - July 29 at 10:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals logo

Ayala Pharmaceuticals

NASDAQ:ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Capricor Therapeutics logo

Capricor Therapeutics

NASDAQ:CAPR
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Kaya logo

Kaya

OTCMKTS:KAYS
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, produces, distributes, and/or sells a range of cannabis products primarily in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, the company provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.

MYOS RENS Technology

NASDAQ:MYOS
MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.